{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:42:05Z","timestamp":1789094525320,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12012-024-09906-w","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:21:47Z","timestamp":1722453707000},"page":"1168-1173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report"],"prefix":"10.1007","volume":"24","author":[{"given":"Andrea","family":"Villatore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pomaranzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cigliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Vignale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Peretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"9906_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","author":"N Palaskas","year":"2020","unstructured":"Palaskas, N., Lopez-Mattei, J., Durand, J. B., Iliescu, C., & Deswal, A. (2020). Immune checkpoint inhibitor myocarditis: Pathophysiological characteristics, diagnosis, and treatment. Journal of the American Heart Association. https:\/\/doi.org\/10.1161\/JAHA.119.013757","journal-title":"Journal of the American Heart Association"},{"issue":"5","key":"9906_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/J.JACCAO.2022.09.004","volume":"4","author":"S Tan","year":"2022","unstructured":"Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022). Immune checkpoint inhibitor therapy in oncology: Current uses and future directions: JACC: Cardiooncology state-of-the-art review. JACC Cardio Oncolgy, 4(5), 579\u2013597. https:\/\/doi.org\/10.1016\/J.JACCAO.2022.09.004","journal-title":"JACC Cardio Oncolgy"},{"issue":"18","key":"9906_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., & Becker, J. R. (2016). Fulminant myocarditis with combination immune checkpoint blockade. New England Journal of Medicine, 375(18), 1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"9906_CR4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1148\/radiol.2021210814","volume":"301","author":"A Faron","year":"2021","unstructured":"Faron, A., Isaak, A., Mesropyan, N., Reinert, M., Schwab, K., Sirokay, J., Sprinkart, A. M., Bauernfeind, F. G., Dabir, D., Pieper, C. C., & Heine, A. (2021). Cardiac MRI depicts immune checkpoint inhibitor-induced myocarditis: A prospective study. Radiology, 301(3), 602\u2013609. https:\/\/doi.org\/10.1148\/radiol.2021210814","journal-title":"Radiology"},{"issue":"1","key":"9906_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/S41379-019-0363-0","volume":"33","author":"SN Champion","year":"2020","unstructured":"Champion, S. N., & Stone, J. R. (2020). Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Modern Pathology, 33(1), 99\u2013108. https:\/\/doi.org\/10.1038\/S41379-019-0363-0","journal-title":"Modern Pathology"},{"issue":"5","key":"9906_CR6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/J.JACCAO.2022.11.005","volume":"4","author":"J Moslehi","year":"2022","unstructured":"Moslehi, J., & Salem, J. E. (2022). Immune checkpoint inhibitor myocarditis treatment strategies and future directions. Cardio Oncology, 4(5), 704\u2013707. https:\/\/doi.org\/10.1016\/J.JACCAO.2022.11.005","journal-title":"Cardio Oncology"},{"issue":"8","key":"9906_CR7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/S40264-015-0300-1","volume":"38","author":"RR Shah","year":"2015","unstructured":"Shah, R. R., & Morganroth, J. (2015). Update on cardiovascular safety of tyrosine kinase inhibitors: With a special focus on QT interval, left ventricular dysfunction and overall risk\/benefit. Drug Safety, 38(8), 693\u2013710. https:\/\/doi.org\/10.1007\/S40264-015-0300-1","journal-title":"Drug Safety"},{"issue":"7","key":"9906_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., & Gianoukakis, A. G. (2015). Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New England Journal of Medicine, 372(7), 621\u2013630. https:\/\/doi.org\/10.1056\/NEJMoa1406470","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"9906_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-021-00817-2","volume":"16","author":"A Goldman","year":"2021","unstructured":"Goldman, A., Bomze, D., Dankner, R., Fourey, D., Boursi, B., Arad, M., & Maor, E. (2021). Cardiovascular toxicities of antiangiogenic tyrosine kinase inhibitors: A retrospective, pharmacovigilance study. Targeted Oncology, 16(4), 471\u2013483. https:\/\/doi.org\/10.1007\/s11523-021-00817-2","journal-title":"Targeted Oncology"},{"key":"9906_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2020.00891","author":"Y Jin","year":"2020","unstructured":"Jin, Y., Xu, Z., Yan, H., He, Q., Yang, X., & Luo, P. (2020). A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors. Frontiers in Pharmacology. https:\/\/doi.org\/10.3389\/FPHAR.2020.00891","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"9906_CR11","doi-asserted-by":"publisher","DOI":"10.14797\/MDCJ-14-3-E5","volume":"14","author":"M Asawaeer","year":"2018","unstructured":"Asawaeer, M., Barton, D., Radio, S., & Chatzizisis, Y. S. (2018). Tyrosine kinase inhibitor-induced acute myocarditis, myositis, and cardiogenic shock. Methodist DeBakey Cardiovascular Journal, 14(3), e5. https:\/\/doi.org\/10.14797\/MDCJ-14-3-E5","journal-title":"Methodist DeBakey Cardiovascular Journal"},{"key":"9906_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/circ.146.suppl_1.15424","author":"J Del Cid Fratti","year":"2022","unstructured":"Del Cid Fratti, J., Gara, R., Reque\u00f1a, C., & Bhardwaj, C. (2022). Abstract 15424: The toxic tango: Tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) toxicities. Circulation. https:\/\/doi.org\/10.1161\/circ.146.suppl_1.15424","journal-title":"Circulation"},{"issue":"3","key":"9906_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/J.JCCASE.2022.04.012","volume":"26","author":"H Ishiguchi","year":"2022","unstructured":"Ishiguchi, H., Uchida, M., Okamura, T., Kobayashi, S., & Yano, M. (2022). Acute heart failure following the initiation of cabozantinib, a multikinase inhibitor: A case report. Journal of Cardiology Cases, 26(3), 217\u2013220. https:\/\/doi.org\/10.1016\/J.JCCASE.2022.04.012","journal-title":"Journal of Cardiology Cases"},{"issue":"6","key":"9906_CR14","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/bcp.13895","volume":"85","author":"R Iacovelli","year":"2019","unstructured":"Iacovelli, R., Ciccarese, C., Fornarini, G., Massari, F., Bimbatti, D., Mosillo, C., Rebuzzi, S. E., Di Nunno, V., Grassi, M., Fantinel, E., & Ardizzoni, A. (2019). Cabozantinib-related cardiotoxicity: A prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. British Journal of Clinical Pharmacology, 85(6), 1283\u20131289. https:\/\/doi.org\/10.1111\/bcp.13895","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"22","key":"9906_CR15","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., & Thamake, S. (2021). Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease. New England Journal of Medicine, 385(22), 2036\u20132046. https:\/\/doi.org\/10.1056\/NEJMoa2103425","journal-title":"New England Journal of Medicine"},{"key":"9906_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000548","author":"Q Lin","year":"2013","unstructured":"Lin, Q., Huang, Y., Booth, C. J., Haase, V. H., Johnson, R. S., Celeste Simon, M., Giordano, F. J., & Yun, Z. (2013). Activation of hypoxia-inducible factor-2 in adipocytes results in pathological cardiac hypertrophy. Journal of the American Heart Association. https:\/\/doi.org\/10.1161\/JAHA.113.000548","journal-title":"Journal of the American Heart Association"},{"issue":"9","key":"9906_CR17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","volume":"36","author":"KD Courtney","year":"2018","unstructured":"Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., & Josey, J. A. (2018). Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma. Journal of Clinical Oncology, 36(9), 867\u2013874. https:\/\/doi.org\/10.1200\/JCO.2017.74.2627","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-024-09906-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-024-09906-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-024-09906-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T14:05:53Z","timestamp":1727791553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-024-09906-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["9906"],"URL":"https:\/\/doi.org\/10.1007\/s12012-024-09906-w","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"27 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}